Franklin Lakes-based BD (Becton, Dickinson and Company), a global leader in medical technology, on Thursday announced the appointment of Vitor Roque as executive vice president and chief financial officer, effective immediately.
Roque, who has been serving as the company’s interim CFO since December 2025, was selected following a comprehensive search process. His permanent appointment marks a seamless transition for the Franklin Lakes-based company as it continues to execute its long-term “New BD” strategy.
Roque is a BD veteran with over 25 years of service at the company. Before taking on the interim CFO role, he served as senior vice pesident of Finance and Corporate Financial Planning and Analysis. His tenure at BD has been characterized by deep institutional knowledge and hands-on leadership across finance, manufacturing, and global operations.
“Following a comprehensive search process, it was clear that Vitor is the right leader to serve as BD’s next CFO,” Tom Polen, chairman, CEO, and president of BD. “Vitor brings an unmatched understanding of our business, a proven ability to translate strategy into performance, and the discipline to drive consistent execution at scale.”
During his time as interim CFO, Roque was instrumental in several high-priority initiatives, most notably the successful separation of BD’s Biosciences & Diagnostic Solutions business, which was completed ahead of schedule.
His background is uniquely global; having lived and worked in multiple countries, Roque possesses a nuanced understanding of the regional dynamics critical to a medical technology giant with a worldwide footprint. This perspective is expected to help BD increase organizational speed and elevate financial discipline across its international business units.
In his new role, Roque will focus on driving consistent financial performance and increasing value for both shareholders and healthcare customers.
“I see tremendous opportunity ahead – with a clear, well-defined strategy to unlock significant growth and increase our impact on global healthcare,” Roque said. “BD is well positioned to drive consistent performance, deliver durable growth, and increase shareholder value creation as we continue to deliver on our purpose of advancing the world of health.”
